-IBIS-1.7.0-
tx
musculoskeletal system
osteoarthritis
Nutrition

dietary guidelines

eating principles:
• low sugar
• low fat diet of unsaturated fats
• calorie percentages: 70% complex carbohydrates, protein 12-15%, fat 15-18%
• short fasts (5-7 days) are recommended with 2 week intervals between them
• vegetarian cleansing diet
• elimination/rotation diet, rotation diet, rotation diet expanded

fresh juices:
• black mission figs, raw goat's milk (Jensen B. 61.)
• black cherry (Jensen B. 61.)
• green kale (Jensen B. 61.)
• celery, parsley (Jensen B. 61.)
• veal joint broth (Jensen B. 61.)
• celery and parsley juice or tea (decoct 7-8 minutes) (Shefi E.)
• cucumber, endive, and goat's whey (Jensen B.)
• celery and apple

therapeutic foods:
• sesame seeds, kale, artichokes, green beans, millet, celery, barley, okra, almonds, collards, turnip greens, raw goat's milk, goat whey and black mission figs, gelatin (make a gelatin mold with cherry concentrate and no sugar), burdock root, cherries, pineapple, quince, watercress, blackberries, black currants, mustard greens, limes, lettuce, olive oil
sesame seed, kale, millet, celery, barley, okra, almonds, collards, turnip greens, raw goat milk (Jensen B. 61.)

avoid:
vegetables from the nightshade (Solanaceae) family: tomatoes, green peppers, cayenne potatoes, pimentoes, eggplant, tobacco
Note: It may take 4-6 weeks to clear out all of the solanacean compounds from the body.
• animal products, cow's milk and other dairy products due to promotion of PGE2 pro-inflammatory mediators
• spinach, asparagus, rhubarb, coffee, caffeine, sugar, refined foods, fried foods
• food intolerances

» Cold-type Arthritis:
therapeutic foods
• garlic, green onions, pepper, black beans, sesame seeds, chicken, lamb, mustard greens, ginger, small amount of rice wine if no hypertension, spicy foods, grapes, grapevine, parsnip, Warming foods (Ni. 103.)

specific remedies:
• rub garlic or ginger on painful areas (Ni. 103.)
• drink scallion tea and rub on painful areas (Ni. 103.)
• rub rice wine on painful areas and drink one shot glass in evening (Ni. 103.)
• drink grapevine tea added to red wine
• tea from parsnip, cinnamon, black pepper, and dried ginger (Ni. 103.)

avoid:
• raw foods, Cold or Cooling foods (Ni. 103)

Wind type Arthritis:
therapeutic foods
• scallions, grapes, grapevine and mulberry vine tea, black beans, most grains, leafy green vegetables, foods that disperse Wind (Ni. 104.)

avoid:
• meats, shellfish, sugar alcohol, smoking, stimulating foods (Ni. 104.)

Damp-type Arthritis:
therapeutic foods
• barley, mung beans, mustard greens, red beans, millet, sweet rice wine with meals, cornsilk tea, diuretic foods, foods that rid Damp (Ni. 104.)

specific remedies:
• cook together barley, mung beans and red beans (Ni. 104.)
• drink cornsilk tea (Ni. 104.)

avoid:
• cold foods, raw foods, dairy products, tofu, Damp foods (Ni. 104.)

Heat -type Arthritis:
therapeutic foods
• fresh fruits and vegetables, dandelion, cabbage, mung beans, winter melon, soybeans (Ni. 104.)

avoid:
• spicy foods, alcohol, smoking, stress, green onions, cinnamon, Hot or Warming foods (Ni. 104.)


supplements

Niacinamide (Vitamin B3): 800 mg three times daily. Monitor liver enzymes. If the patient is suffering from nausea, liver enzymes are elevated. However, 10% of the population may have elevated liver enzymes without experiencing nausea.
• Vitamin B5: 500 mg per day.
• Vitamin B6: 100 mg three times daily. This treatment is especially effective for menopausal or rheumatic-type arthritis
• Vitamin C: 1-2 g per day.
Vitamin D, 400 IU twice daily, can increase intestinal absorption of calcium when taken together.
• Vitamin E: 400-1600 IU per day.
Boron (Traver RL, et al. J Nut Med 1990;1:127-132.)
Calcium 1000-1500 mg per day. Calcium supplementation provides the greatest preventive effect when taken years, even decades, before menopause and periods of increased risk. Postmenopausal women on a hormonal support program should take 1,000-1,500 mg per day; those not on hormonal support should take at least 1,500 mg per day. Absorption is usually enhanced if taken with meals. Taking calcium before bedtime can also provide a gentle sedative effect. While there are generally assumed to be no known adverse effects at doses up to 2,500 mg per day, calcium carbonate may cause constipation or digestive distress in many individuals. Some research indicates that calcium citrate or hydroxyapatite may provide superior ability to support bone.
Magnesium 500 mg per day.
• Selenium: 200 mcg per day.
DL-phenylalanine: 250 mg, three to four times per day; researchers found that subjects typically began to expertience pain relief beginning in four to five weeks.
S-Adenosyl-L-methionine (SAMe)
• Essential fatty acids: 2 Tbsp per day.
• Cod liver oil: 2 Tbsp per day.
• Dimethyl sulfoxide (DMSO)
Glucosamine sulfate: 300-500 mg, three times daily.
Glycosaminoglycans (green lipped muscle extract)
• Yucca saponin extract (Bingham R J. Applied Nutr. 1975;27:45-50.)


» drug interaction:
• Vitamin D: colestipol (Colestid) interferes with absorption of vitamin D; calcium should also be supplemented due to decreased absorption of vitamin D
• Potassium and indomethacin (Indocin): as a prostaglandin inhibitor, indomethacin reduces renin and aldosterone, and consequently reduces potassium excretion and causes hyperkalemia.
(Goldszer, et al. 1981;141:802-804; Tan, et al. 1979;90:783-785; MacCarthy, et al. 1979;1:550.)
• Calcium and thyroid medication [dessicated thyroid, Synthroid (T4), Cytomel (T3)]: causes increased urinary excretion of Calcium.
(Paul, et al. 1988;259:3137-3141; Kung and Pun, 1991;265: 2688-2691; Adlin, et al. 1992;128:210-213.)


footnotes

Altman R, Gray R. Inflammation in osteoarthritis. Clin Rheum Dis 1985;11:353.

Altman RD, Lozada CJ. Practice guidelines in the management of osteoarthritis. Osteoarthritis Cartilage 1998;6(Suppl A):22-24. (Review)

American Medical Association. Dimethyl sulfoxide. Controversy and Current Status - 1981. JAMA 1982;248:1369-1371.

Baici A, Hörler D, Moser B, et al. Analysis of glycosaminoglycans in human serum after oral administration of chondroitin sulfate. Rheumatol Int 1992;12:81-88.

Balagot RC, Ehrenpreis S, Kubota K, Greenberg J. Analgesia in mice and humans by D-phenylalanine: Relation to inhibition of enkephalin degradation and enkephalin levels. In: Advances in Pain Research and Therapy, Vol 5, Bonica JJ, Liebeskind JC, Albe-Fessard DG, eds, Raven Press, New York, 1983, 289-293.

Barclay TS, Tsourounis C, McCart GM. Glucosamine. Ann Pharmacother 1998;32(5):574-579.

BarShalom R, Soileau J. (eds.) Natural Health Hotline. Beaverton, OR: Integrative Medical Arts, 1991-1999.

Bazières B, Loyau G, Menkès CJ, et al. Le chondroïtine sulfate dans le traitement de la gonarthrose et de la coxarthrose. Rev Rhum Mal Ostéoartic 1992;59:466-472.

Bingham R, Bellow BA, Bellow JG. Yucca plant saponin in the management of arthritis. J Appl Nutr 1975;27:45-51.
Abstract: 149 arthritis patients were studied, of which 58.9% were found to have OA. Compared to placebo, from 1 week to 15 months, 61% of the yucca extract patients noted less swelling, pain and stiffness as compared to 22% of Placebo. There was a lot of variability in the time of onset of improvement.

Blankenhorn G. Klinische Wirtsamkeit von Spondyvit (vitamin E) bei aktiverten arthronsen. Z Orthop 1986;124:340-343.

Bourgeois P, Chales G, Dehais J, et al. Efficacy and tolerability of chondroitin sulfate 1200 mg/day vs chondroitin sulfate 3X400 mg/day vs placebo. Osteoarthritis Cartilage 1998;6(Suppl A):25-30.

Bucsi L, Poór G. Efficacy and tolerability of oral chondroitin sulfate as a symptomatic slow-acting drug for osteoarthritis (SYSADOA) in the treatment of knee osteoarthritis. Osteoarthritis Cartilage 1998;6(Suppl A):31-36.

Budd K. Use of D-phenylalanine, an enkephalinase inhibitor, in the treatment of intractable pain. In: Advances in Pain Research and Therapy, Vol 5, Bonica JJ, Liebeskind JC, Albe-Fessard DG, eds, Raven Press, New York, 1983, 305-308.

Caruso I, Pietrogrande V. Italian double-blind multicenter study comparing S-adenosylmethionine, naproxen, and placebo in the treatment of degenerative joint disease. Am J Med 1987;83(suppl 5A):66-71.

Childers NF, Margoles MS. An apparent relation of nightshades (Solanaceae) to arthritis. J Neurol Orthop Med Surg 1993;14:227-231.

Childers NF. A relationship of arthritis to the solanaceae (nightshades). J Internat Acad Pre Med 1982;Nov:31-37.

Conrozier T, Vignon E. Die Wirkung von Chondroitinsulfat bei der Behandlung der Hüft Gelenksarthrose. Eine Doppelblindstudie gegen Placebo. Litera Rheumatologica 1992;14:69-75.

Conte A, Volpi N, Palmieri L, et al. Biochemical and pharmacokinetic aspects of oral treatment with chondroitin sulfate. Arzneim-Forsch 1995;45:918-925.

Crolle G, DiEste E. Glucosamine sulfate for the management of arthrosis. Curr Ther Res 1980;7:104-109.

D’Ambrosio E, Casa B, Bompani G, et al. Glucosamine sulphate: a controlled clinical investigation in arthrosis. Pharmatherapeutica 1981;2(8):504-508.

da Camara CC, Dowless GV. Glucosamine sulfate for osteoarthritis. Ann Pharmacother 1998;32:580-587.

Domljan Z et al. A double-blind trial of ademetionine vs naproxen in activated gonarthrosis. Int J Clin Pharmacol Ther Toxicol 1989;27:329-333.

Drovanti A, Bignamini AA, Rovati AL. Therapeutic activity of oral glucosamine sulfate in osteoarthritis: a placebo-controlled double-blind investigation. Clin Ther 1980;3(4):260-272.

Giordano N, Nardi P, Senesi M, et al. The efficacy and safety of glucosamine sulfate in the treatment of gonarthritis. Clin Ter 1996;147:99-105.

Glorioso S, Todesco S, Mazzi A, et al. Double-blind multicentre study of the activity of S-adenosylmethionine in hip and knee osteoarthritis. Int J Clin Pharmacol Res 1985;5:39-49.

Harmand MF, Vilamitjana J, Maloche E, et al. Effects of S-adenosylmethionine on human articular chondrocyte differentiation: An in vitro study. Am J Med 1987;83(suppl 5A):48-54.

Helliwell TR, Kelly SA, Walsh HP, et al. Elemental analysis of femoral bone from patients with fractured neck of femur or osteoarthrosis. Bone 1996;18:151-157.

Hoffer A. Treatment of arthritis by nicotinic acid and nicotinamide. Can Med Assoc J 1959;81:235-238.

Jacob SW, Wood DC. Dimethyl sulfoxide (DMSO). Toxicology, pharmacology, and clinical experience. Am J Surg 114:414-426.

Jimenez RAH, Willkens RF. Dimethyl sulfoxide: A perspective of its use in rheumatic diseases. J Lab Clin Med 1982;100:489-500.

Jonas WB, Rapoza CP, Blair WF. The effect of niacinamide on osteoarthritis: A pilot study. Inflamm Res 1996;45:330-334.

Kaufman W. The use of vitamin therapy for joint mobility. Therapeutic reversal of a common clinical manifestation of the ‘normal’ aging process. Conn State Med J 1953;17(7):584-589.

Kaufman W. The use of vitamin therapy to reverse certain concommitants of aging. J Am Geriatr Soc 1955;11:927.

Kerzberg EM, Roldán EJA, Castelli G, Huberman ED. Combination of glycosaminoglycans and acetylsalicylic acid in knee osteoarthrosis. Scand J Pheumatol 1987;16:377-380.

Konig H, et al. Magnetic resonance tomography of finger polyarthritis: Morphology and cartilage signals after ademetionine therapy. Aktuelle Radiol 1995;5:36-40.

L’Hirondel JLL. Klinische Doppelblind-Studie mit oral verabreichtem Chondroitinsulfat gegen Placebo bei der tibiofermoralen Gonarthrose (125 Patienten). Litera Rheumatologica 1992;14:77-82.

Leeb BF, Petera P, Neumann K. Results of a multicenter study of chondroitin sulfate (Condrosulf) use in arthroses of the finger, knee and hip joints. Wien Med Wochenschr 1996;146:609-614.

Maccagno A. Double-blind controlled clinical trial of oral S-adenosylmethionine versus piroxicam in knee osteoarthritis. Am J Med 1987;83 (suppl 5A):72-77.

Machtey I, Ouaknine L. Tocopherol in osteoarthritis: a controlled pilot study. J Am Geriatr Soc 1978;25(7):328-330.

Marcolongo R, Giordano N, Colombo B, et al. Double-blind multicentre study of the activity of s-adenosyl-methionine in hip and knee osteoarthritis. Curr Ther Res 1985;37:82-94.

McAlindon TE, Jacques P, Azang Y. Do antioxidant micronutrients protect against the development and progression of knee osteoarthritis? Arthrit Rheum 1996;39:648-656.

Montrone F, Fumagalli M, Sarzi Puttini P, et al. Double-blind study of S-adenosyl-methionine versus placebo in hip and knee arthrosis. Clin Rheumatol 1985;4:484-485.

Morreale P, Manopulo R, Galati M, et al. Comparison of the antiinflammatory efficacy of chondroitin sulfate and diclofenac sodium in patients with knee osteoarthritis. J Rheumatol 1996;23:1385-1391.

Muller-Fassbender H. Double-blind clinical trial of S-adenosylmethionine in versus ibuprofen in the treatment of osteoarthritis. Am J Med 1987;83(suppl 5A):81-83.

Murray MT. Which is better: Aged versus fresh garlic; glucosamine sulfate versus chondroitin sulfate. Am J Natural Med 1997;4:5-8.

Newnham RE. The role of boron in human nutrition. J Applied Nutr 1994;46:81-85.

Pipitone V, Ambanelli U, Cervini C, et al. A multicenter, triple-blind study to evaluate galactosaminoglucuronoglycan sulfate versus placebo in patients with femorotibial gonarthritis. Curr Ther Res 1992;52:608-638.

Prudden JF, Balassa LL. The biological activity of bovine cartilage preparations. Semin Arthritis Rheum 1974;3:287-320.

Pujalte JM, Llavore EP, Ylescupidez FR. Double-blind clinical evaluation of oral glucosamine sulphate in the basic treatment of osteoarthrosis. Curr Med Res Opin 1980;7(2):110-114.

Qiu GX, Gao SN, Giacovelli G, et al. Efficacy and safety of glucosamine sulfate versus ibuprofen in patients with knee osteoarthritis. Arzneimforsch Drug Res 1998;48:469-474.

Reichelt A, Förster KK, Fischer M, et al. Efficacy and safety of intramuscular glucosamine sulfate in osteoarthritis of the knee. Arzneimforsch Drug Res 1994;44:75-80.

Reijholec V. Long term studies of antiosteoarthritic drugs: an assessment. Semin Arthritis Rheum 1987;17(2 Suppl 1):35-53.

Ronca F, Palmieri L, Panicucci P, Ronca G. Anti-inflammatory active of chondroitin sulfate. Osteoarthritis Cartilage 1998;6(Suppl A):14-21.

Rovetta G. Galactosaminoglycuronoglycan sulfate (Matrix) in therapy of tibiofibular osteoarhtirits of the knee. Drugs Exptl Clin Res 1991;17:53-57.

Scherak O, Kolarz G, Schödl Ch, Blankenhorn G. Hochdosierte Vitamin-E-Therapie bei Patienten mit aktivierter Arthrose. Z Rheumatol 1990;49:369-373.

Schumacher HR. Osteoarthritis: The clinical picture, pathogenesis, and management with studies on a new therapeutic agent, S-adenosylmethionine. Am J Med 1987;83(suppl 5A):1-4. (Review)

Seltzer S, Marcus R, Stoch R. Perspectives in the control of chronic pain by nutritional manipulation. Pain 1981;11:141-48. (Review)

Stammers T, Sibbald B, Freeling P. Fish oil in osteoarthritis. Lancet 1989;ii:503. (Letter)

Tapadinhas MJ, Rivera IC, Bignamini AA. Oral glucosamine sulphate in the management of arthrosis: report on a multi-centre open investigation in Portugal. Pharmtherapeutica 1982;3:157-168.

Taylor MR. Food allergy as an etiological factor in arthropathies: a survey. J Internat Acad Prev Med 1983;8:28-38. (Review)

Theodosakis J, Adderly B, Fox B. The Arthritis Cure. St. Martin’s Press, New York, 1997.

Travers RL, Rennie GC, Newnham RE. Boron and arthritis: the results of a double-blind pilot study. J Nutr Med 1990;1:127-132.
Abstract: 20 patients were studied in a double blind trial comparing 6mg/day boron with a placebo. Of the 10 patients on boron, 5 improved. Only 1 of 10 in the placebo group improved. The boron had a significant benefit for those patients with severe osteoarthritis. The 6 mg boron was administered in 2 tablets containing 25mg borax (sodium tetraborate decahydrate). The experiment was carried over an 8 week period. There were no side effects.